Construction of a risk stratification model integrating ctDNA to predict response and survival in neoadjuvant-treated breast cancer - Liu, Zhaoyun; Yu, Bo; Su, Mu; Yuan, Chenxi; Liu, Cuicui; Wang, Xinzhao; Song, Xiang; Li, Chao; Wang, Fukai; Ma, Jianli; Wu, Meng; Chen, Dawei; et al. (BMC medicine, 2023)
Keywords: Analysis; Anthracycline; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols - therapeutic use; Biomarkers; Biopsy; Blood; Breast cancer; Breast Neoplasms - drug therapy; Breast Neoplasms - genetics; Breast Neoplasms - pathology; Cancer; Cancer patients; Care and treatment; Chemotherapy; Copy number; ctDNA; Customization; Deoxyribonucleic acid; Diagnosis; DNA; DNA Copy Number Variations; DNA sequencing; ErbB-2 protein; Evaluation; Female; Forkhead Transcription Factors; Foxp1 protein; Gene sequencing; Genes; Genetic aspects; Hospitals; Humans; Identification and classification; Interleukin 7 receptors; Mammography; Medical prognosis; Medical research; Medicine, Experimental; Metastases; MSH2 protein; Mutation; Neoadjuvant chemotherapy; Neoadjuvant Therapy; Nucleotide sequencing; Nucleotides; p53 Protein; Patient outcomes; Patients; pCR; Pertuzumab; Plasma; Polymerase chain reaction; Prediction model; Prediction models; Pretreatment; Prognosis; Repressor Proteins - genetics; Repressor Proteins - therapeutic use; Risk Assessment; Surgery; Survival; Test sets; Tumor proteins; Tumors; China; United States--US; Neoadjuvant chemotherapy; Breast cancer; ctDNA; pCR; Prediction model